ORY.MC BME
Oryzon Genomics S.A.
1W: +0.0%
1M: -2.9%
3M: -7.8%
YTD: -13.1%
1Y: +2.2%
3Y: +33.2%
5Y: -15.7%
€2.73 ($3.07)
-0.02 (-0.80%)
Weekly Expected Move ±2.5%
€3
€3
€3
€3
€3
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
#3
of 5
Biotechnology
Technical Signal Map
0 Bullish
0 Neutral
5 Bearish
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| ORY.MC Oryzon Genomics S.A. | $220M | -87.6 | -4.0 | -1.4 | — | -59.8 | 1 | BEARISH | 2.2 |
| ATRY.MC Atrys Health, S.A. | $200M | -2.0 | -58.3 | -6.0 | -8.2 | -19.6 | 5 | BEARISH | -9.2 |
| 0RC6.IL Pharma Mar S.A. | $1.2B | — | — | — | — | — | — | BEARISH | — |
| PHM.MC Pharma Mar, S.A. | $1.6B | 21.9 | 24.8 | 35.2 | -2.0 | 15.5 | 8 | BEARISH | -12.2 |
| BST.MC Biotechnologies Assets S.A. | $10M | -6.9 | -75.2 | -50.2 | -51.3 | -7.2 | 4 | BEARISH | -59.0 |
| ORY.MC Oryzon Genomics S.A. | $220M | -87.6 | -4.0 | -1.4 | — | -59.8 | 1 | BEARISH | 2.2 |
| ATRY.MC Atrys Health, S.A. | $200M | -2.0 | -58.3 | -6.0 | -8.2 | -19.6 | 5 | BEARISH | -9.2 |
| 0RC6.IL Pharma Mar S.A. | $1.2B | — | — | — | — | — | — | BEARISH | — |
| PHM.MC Pharma Mar, S.A. | $1.6B | 21.9 | 24.8 | 35.2 | -2.0 | 15.5 | 8 | BEARISH | -12.2 |
| BST.MC Biotechnologies Assets S.A. | $10M | -6.9 | -75.2 | -50.2 | -51.3 | -7.2 | 4 | BEARISH | -59.0 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
ORY.MC vs Benchmarks
ROIC
Revenue Growth
P/E Ratio
ROE
Piotroski F